Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Rapport Therapeutics is a biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders. Its platform targets neuronal receptor complexes, such as TARP-8 and nAChRs, to create highly selective therapies with improved safety profiles. The company’s lead candidate, RAP-219, aims to treat focal epilepsy, bipolar disorder, and neuropathic pain by precisely modulating brain region-specific receptors, reducing side effects and drug interactions.
This description was generated via AI from an annual report. Updated about 1 year ago.